Motavizumab

Jump to: navigation, search
Motavizumab
Monoclonal antibody
TypeWhole antibody
SourceTemplate:Infobox drug/mab source
TargetRSV glycoprotein F
Clinical data
Trade namesNumax
Routes of
administration
i.v.
ATC code
Pharmacokinetic data
Protein bindingNone
Identifiers
CAS Number
ChemSpider
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6476H10014N1706O2008S48
Molar massApproximately 148 kDa
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Motavizumab

Articles

Most recent articles on Motavizumab

Most cited articles on Motavizumab

Review articles on Motavizumab

Articles on Motavizumab in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Motavizumab

Images of Motavizumab

Photos of Motavizumab

Podcasts & MP3s on Motavizumab

Videos on Motavizumab

Evidence Based Medicine

Cochrane Collaboration on Motavizumab

Bandolier on Motavizumab

TRIP on Motavizumab

Clinical Trials

Ongoing Trials on Motavizumab at Clinical Trials.gov

Trial results on Motavizumab

Clinical Trials on Motavizumab at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Motavizumab

NICE Guidance on Motavizumab

NHS PRODIGY Guidance

FDA on Motavizumab

CDC on Motavizumab

Books

Books on Motavizumab

News

Motavizumab in the news

Be alerted to news on Motavizumab

News trends on Motavizumab

Commentary

Blogs on Motavizumab

Definitions

Definitions of Motavizumab

Patient Resources / Community

Patient resources on Motavizumab

Discussion groups on Motavizumab

Patient Handouts on Motavizumab

Directions to Hospitals Treating Motavizumab

Risk calculators and risk factors for Motavizumab

Healthcare Provider Resources

Symptoms of Motavizumab

Causes & Risk Factors for Motavizumab

Diagnostic studies for Motavizumab

Treatment of Motavizumab

Continuing Medical Education (CME)

CME Programs on Motavizumab

International

Motavizumab en Espanol

Motavizumab en Francais

Business

Motavizumab in the Marketplace

Patents on Motavizumab

Experimental / Informatics

List of terms related to Motavizumab

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.[1]

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.[2]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[3]

References

  1. ClinicalTrials.gov
  2. "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.
  3. "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.

Linked-in.jpg